CCM Investment Advisers Portfolio holdings
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Vertex Pharmaceuticals
VRTX
|
+$12.3M |
| 2 |
Eli Lilly
LLY
|
+$9.63M |
| 3 |
Equinix
EQIX
|
+$7.6M |
| 4 |
Netflix
NFLX
|
+$3.34M |
| 5 |
Procter & Gamble
PG
|
+$1.04M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Omnicom Group
OMC
|
+$13.5M |
| 2 |
CVS Health
CVS
|
+$12.8M |
| 3 |
Gilead Sciences
GILD
|
+$10M |
| 4 |
Realty Income
O
|
+$6.81M |
| 5 |
Tyson Foods
TSN
|
+$5.69M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 28.95% |
| 2 | Healthcare | 12.5% |
| 3 | Financials | 12.21% |
| 4 | Consumer Discretionary | 10.45% |
| 5 | Communication Services | 9.12% |
Similar funds
CCM Investment Advisers's Q1 2024 Portfolio in Review
As of Q1 2024, CCM Investment Advisers held 78 positions worth $836M, up 2.9% from $813M the previous quarter. Its ten largest holdings account for 29% of the portfolio.
CCM Investment Advisers withdrew a net $69.4M in Q1 2024, closing 3 positions and reducing 54 holdings. Its most notable exit was Bristol-Myers Squibb, an estimated $821K position sold in full.
By sector, the portfolio is most concentrated in Technology at 29% of assets, up from 29% a quarter earlier, followed by Healthcare and Financials.
Against the trend, CCM Investment Advisers opened a new position in Vertex Pharmaceuticals worth $12.2M.
- CCM Investment Advisers's largest Q1 2024 buy was Vertex Pharmaceuticals: 29,185 shares worth $12.2M.
- CCM Investment Advisers added most to Eli Lilly in Q1 2024, an estimated $9.63M increase.
- CCM Investment Advisers's biggest Q1 2024 reduction was Omnicom Group, cutting an estimated $13.5M.
- CCM Investment Advisers fully exited Bristol-Myers Squibb in Q1 2024, selling an estimated $821K.
- CCM Investment Advisers's ten largest holdings make up 29% of its $836M portfolio in Q1 2024.
- CCM Investment Advisers opened 3 new positions and closed 3 in Q1 2024.
- CCM Investment Advisers's portfolio value rose 2.9% quarter-over-quarter to $836M.
Based on CCM Investment Advisers's 13F filing for Q1 2024, filed 17 May 2024.